Table 3. Summary of the meta-analysis.
| Endpoint | All RCTs | RCTs comparing DOX vs DOX-based combination therapy | ||
|---|---|---|---|---|
| HR/OR (95% CI) | P | HR/OR (95% CI) | P | |
| OS | 0.97 (0.91–1.03) | 0.28 | 0.92 (0.82–1.03) | 0.13 |
| 1-year OS | 0.88 (0.79–0.99) | 0.03 | 0.82 (0.72–0.94) | 0.004 |
| 2-year OS | 0.87 (0.73–1.03) | 0.11 | 0.84 (0.67–1.05) | 0.14 |
| PFS | 1.02 (0.91–1.13) | 0.74 | 0.91 (0.85–0.99) | 0.02 |
| 3-month PFS | 1.11 (0.85–1.46) | 0.43 | 0.77(0.58–1.01) | 0.06 |
| 6-month PFS | 0.91 (0.73–1.15) | 0.44 | 0.81 (0.61–1.06) | 0.13 |
| 1-year PFS | 0.88 (0.69–1.13) | 0.33 | 0.77 (0.64–0.91) | 0.003 |
| 2-year PFS | 0.88 (0.70–1.09) | 0.23 | 1.04 (0.81–1.33) | 0.78 |
| RR | 1.11 (0.85–1.46) | 0.45 | 0.76 (0.60–0.97) | 0.03 |
| AEs, overall | 1.20 (0.88–1.65) | 0.26 | 1.81 (1.35–2.43) | <0.0001 |
| Nausea/vomiting | 1.90 (1.27–2.83) | 0.002 | 2.52 (1.47–4.33) | 0.0008 |
| Leukopenia | 1.17 (0.72–1.89) | 0.52 | 2.51 (2.00–3.16) | <0.00001 |
| Neutropenia | 0.79 (0.52–1.21) | 0.28 | 1.08 (0.61–1.93) | 0.79 |
Abbreviations: RCT, randomized controlled trial; DOX, doxorubicin; HR, hazard ratio; OR, odds ratio; CI, confidence interval; OS, overall survival; PFS, progression-free survival; RR, response rate; AEs, adverse events.